Pulmatrix has announced the receipt of US patent No. 9,642,798, titled “Monovalent metal cation dry powders for inhalation,” which covers its PUR0200 dry powder formulation of tiotropium bromide for the treatment of COPD.
In July 2016, Pulmatrix announced positive Phase 1 results for PUR0200. The company has previously received a number of patents for its iSPERSE inhalation powder technology.
Pulmatrix CEO Robert W. Clarke commented, “This patent ensures that the product is protected by intellectual property until 2033. It also is further recognition of the potential medical advances offered by our innovative iSPERSE technology for delivering drugs to the lungs more efficiently. This new patent is another step forward to bringing PUR0200 to market—and to be able to offer new benefits to patients suffering from COPD.”
Read the Pulmatrix press release.
